Related Experiment Videos
Recombinant EWS-FLI1 oncoprotein activates transcription
Aykut Uren1, Olga Tcherkasskaya, Jeffrey A Toretsky
1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Research Building, Room W316, 3970 Reservoir Road, N.W., Box 571469, Washington, DC 20057-1469, USA. au26@georgetown.edu
Biochemistry
|October 20, 2004
Summary
Researchers created a functional EWS-FLI1 protein, crucial for Ewing sarcoma tumors. This recombinant protein aids in understanding tumor mechanisms and finding new treatments for this rare cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Ewing sarcoma family of tumors (ESFT) is characterized by a specific translocation.
- This translocation results in the EWS-FLI1 fusion protein, a key regulator of gene expression.
- EWS-FLI1 is essential for ESFT cell survival and tumor growth.
Purpose of the Study:
- To produce a biologically active recombinant EWS-FLI1 protein.
- To facilitate mechanistic studies of ESFT.
- To identify potential therapeutic targets and inhibitors for ESFT.
Main Methods:
- Cloning and expression of EWS-FLI1 in Escherichia coli.
- Purification using affinity column chromatography.
- Refolding procedures to achieve soluble, native-like conditions.
- Structural analysis using SDS-PAGE, circular dichroism, and fluorescence spectroscopy.
Main Results:
- Successfully produced biologically active recombinant EWS-FLI1.
- Refolding was necessary for solubility and native-like conditions.
- Structural analysis indicated a largely unfolded conformation under native conditions.
- Recombinant EWS-FLI1 demonstrated specific DNA binding and RNA transcription capabilities.
Conclusions:
- Biologically active recombinant EWS-FLI1 has been successfully produced.
- This recombinant protein retains functional activity, including DNA binding and transcription.
- The availability of recombinant EWS-FLI1 will advance research into ESFT mechanisms and therapeutic strategies.